{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-026741","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.480135+00:00","generated_at":"2026-06-27T04:35:27.993112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport FY2021 revenue $222.6M (+183% YoY); Q4 net loss $260.1M on $251.8M debt extinguishment","bullets":["FY2021 revenue $222.6M (+183% YoY); organic revenue from Cryoport Systems & CRYOGENE +40%.","Q4 revenue $56.4M (+17% YoY); Biopharma/Pharma revenue $46.3M (+18%).","Net loss Q4 $260.1M incl $251.8M non-cash debt extinguishment; Adj. EBITDA $0.8M.","Cash & short-term investments $628.8M at Dec 31, 2021; placed $402.5M 0.75% convertible notes.","Supports record 602 clinical trials (273 Phase 2, 74 Phase 3); fire at MVE facility expected Q1 impact $4-5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-026741","json":"https://secwatch.observer/filing/0001104659-22-026741.json","markdown":"https://secwatch.observer/filing/0001104659-22-026741.md","text":"https://secwatch.observer/filing/0001104659-22-026741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922026741/0001104659-22-026741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922026741/tm227658d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:35:27.993112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}